X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 51 filers reported holding X4 PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,202 | -0.8% | 10,277 | +76.6% | 0.00% | – |
| Q2 2023 | $11,293 | +1129200.0% | 5,821 | +618.6% | 0.00% | – |
| Q1 2023 | $1 | -90.0% | 810 | -92.1% | 0.00% | – |
| Q4 2022 | $10 | -99.8% | 10,227 | +81.4% | 0.00% | – |
| Q2 2022 | $5,000 | -68.8% | 5,639 | -41.8% | 0.00% | – |
| Q1 2022 | $16,000 | +128.6% | 9,695 | +675.6% | 0.00% | – |
| Q3 2021 | $7,000 | -91.9% | 1,250 | -90.6% | 0.00% | -100.0% |
| Q2 2021 | $86,000 | +230.8% | 13,231 | +337.7% | 0.00% | – |
| Q1 2021 | $26,000 | -33.3% | 3,023 | -50.6% | 0.00% | -100.0% |
| Q4 2020 | $39,000 | -67.2% | 6,124 | -65.2% | 0.00% | 0.0% |
| Q3 2020 | $119,000 | +310.3% | 17,588 | +470.7% | 0.00% | 0.0% |
| Q2 2020 | $29,000 | -3.3% | 3,082 | +54.6% | 0.00% | -50.0% |
| Q2 2019 | $30,000 | +275.0% | 1,994 | +343.1% | 0.00% | – |
| Q1 2019 | $8,000 | – | 450 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 12,202,510 | $10,616 | 1.33% |
| Tri Locum Partners LP | 3,878,484 | $3,374,281 | 1.03% |
| Lynwood Capital Management Inc. | 900,000 | $783,000 | 0.71% |
| NEA Management Company, LLC | 11,736,793 | $10,211,010 | 0.71% |
| Parkman Healthcare Partners LLC | 2,797,147 | $2,433,518 | 0.53% |
| SCOGGIN MANAGEMENT LP | 484,796 | $567,025 | 0.33% |
| New Leaf Venture Partners, L.L.C. | 335,000 | $291,450 | 0.24% |
| Ghost Tree Capital, LLC | 850,000 | $740,000 | 0.22% |
| Perceptive Advisors | 4,545,454 | $3,954,545 | 0.12% |
| Orbimed Advisors | 5,817,726 | $5,061,422 | 0.10% |